CALL/ROCHE GS/400/0.1/20.12.24 Stock

Warrant

DE000GZ696Y9

Real-time BOERSE MUENCHEN 03:02:49 2024-05-28 am EDT
0.02 EUR 0.00% Intraday chart for CALL/ROCHE GS/400/0.1/20.12.24
Current month-37.50%
3 months-45.95%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-05-28 0.02 0.00%
24-05-27 0.02 -9.09%
24-05-24 0.022 +10.00%
24-05-23 0.02 0.00%
24-05-22 0.02 -13.04%

Real-time BOERSE MUENCHEN

Last update May 28, 2024 at 03:02 am EDT

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying ROCHE HOLDING AG
Issuer Goldman Sachs
WKN GZ696Y
ISINDE000GZ696Y9
Date issued 2022-12-28
Strike 400 CHF
Maturity 2024-12-20 (207 Days)
Parity 10 : 1
Emission price 0.36
Emission volume N/A
Settlement Por diferencias
Currency EUR

Technical Indicators

Highest since issue 0.52
Lowest since issue 0.012
Delta0.03x
Omega 10.41
Premium73.54x
Gearing332.4x
Moneyness 0.5773
Difference Strike 168.6 CHF
Difference Strike %+42.14%
Spread 0.1
Spread %83.33%
Theoretical value 0.0700
Implied Volatility 36.01 %
Total Loss Probability 98.35 %
Intrinsic value 0.000000
Present value 0.0700
Break even 400.69 €
Theta-0.01x
Vega0.01x
Rho0x

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
229.9 CHF
Average target price
279.8 CHF
Spread / Average Target
+21.72%
Consensus